Literature DB >> 7551268

Cost-effectiveness of accepted measures for intervention in coronary heart disease.

K M Kuntz1, T H Lee.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7551268

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN： 0954-6928            Impact factor:   1.439


× No keyword cloud information.
  7 in total

Review 1.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.

Authors:  J C Gillis; K L Goa
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 3.  Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications.

Authors:  W D Bradford; J Chen; H M Krumholz
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

Review 4.  Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.

Authors:  A J Coukell; M I Wilde
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

Review 5.  Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

Authors:  L B Barradell; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

Review 6.  Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.

Authors:  K L Goa; L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

7.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.